Notably, the ATP-competitive dual mTORC1/2 inhibitors PP242 and OSI-027 have shown potent growth inhibitory and pro-apoptotic effects in a number of BCR-ABL cell lines and primary patient samples [47, 48] and in a mouse Ph+ ALL mouse model [48], suggesting that these or other similar agents with dual targeting capacities against TORC1 and TORC2 may provide a new alternative approach for the treatment of CML resistant to TKIs. Here, CRTC1 is linked to acute lymphoblastic leukemia.